Skip to main content
LENZ Therapeutics, Inc. logo

LENZ Therapeutics, Inc. — Investor Relations & Filings

Ticker · LENZ ISIN · US38870X1046 US Manufacturing
Open in API
Filings indexed 329 across all filing types
Latest filing 2023-11-17 Major Shareholding Noti…
Country US United States of America
Listing US LENZ

About LENZ Therapeutics, Inc.

https://lenz-tx.com/

LENZ Therapeutics, Inc. is a late-stage pharmaceutical company focused on developing and commercializing ophthalmic therapies to improve vision. Its primary product is VIZZ™ (aceclidine ophthalmic solution) 1.44%, an FDA-approved eye drop for the treatment of presbyopia, the age-related loss of near vision. VIZZ is the first aceclidine-based therapy for this condition, which affects an estimated 1.8 billion people globally. The product is designed to restore near vision, providing a pharmaceutical alternative to reading glasses for a broad patient population.

Recent filings

Filing Released Lang Actions
SC 13D/A
Major Shareholding Notification
2023-11-17 English
8-K
Merger & Acquisition Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated November 14, 2023, by Graphite Bio, Inc. The content details the entry into a material definitive agreement, specifically a merger agreement between Graphite Bio and Lenz Therapeutics, including terms of the merger, stock exchange ratios, support agreements, lock-up agreements, and a concurrent private placement investment (PIPE). The document is focused on announcing the merger transaction and related financing activities, not a full annual or quarterly report, earnings release, or other financial statement. The presence of detailed merger terms and financing arrangements indicates this is an M&A activity announcement. The document is lengthy (15,000 characters) and contains substantive information about the merger and financing, not just a brief announcement or reference to a report. Therefore, the appropriate classification is Merger & Acquisition (MA).
2023-11-15 English
425 Filing
Regulatory Filings
2023-11-15 English
425 Filing
Regulatory Filings
2023-11-15 English
10-Q
Interim / Quarterly Report Q3 2023
2023-11-13 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the company's entry into a material definitive agreement, specifically a sublease agreement and a lease amendment. There are no financial statements or quarterly/yearly financial results presented, nor is this a transcript, proxy, or governance document. The document is not an announcement of a report publication but a regulatory filing disclosing a material contract event. Therefore, it fits best under Regulatory Filings (RNS). The document length is 6413 characters, which is sufficient for a substantive filing rather than a brief announcement.
2023-10-30 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.